Infektionen und Tumorerkrankungen nach Transplantation

Sebastian Wolf; Joachim Andrassy

doi:10.1055/a-0890-8668

Allgemein- und Viszeralchirurgie up2date, Table of Contents

Allgemein- und Viszeralchirurgie up2date 2019; 13(03): 227-239
DOI: 10.1055/a-0890-8668

Viszerale Transplantationen

Georg Thieme Verlag KG Stuttgart · New York

Infektionen und Tumorerkrankungen nach Transplantation

Sebastian Wolf

,

Joachim Andrassy

Abstract

All articles of this category

Infektionen und Tumorerkrankungen sind Hauptfaktoren für Letalität mit funktionierendem Transplantat. Ziel dieses Artikels ist es, einen Überblick über Inzidenz und Risiko von Infektionen sowie Malignomentstehung bei kontinuierlich immunsupprimierten, organtransplantierten Patienten zu geben, da zunehmend auch Ärzte, die nicht primär in der Transplantationsmedizin arbeiten, transplantierte Patienten betreuen werden.

Schlüsselwörter

Infektionen - Tumorerkrankungen - Transplantation - Malignome

Full Text

References

Literatur
1 DTG. Jahresbericht 2017/18. Regensburg: Deutsche Transplantationsgesellschaft e.V.; 2018
2 DSO. Jahresbericht Organspende und Transplantation in Deutschland 2017. Frankfurt am Main: Deutsche Stiftung Organtransplantation; 2017
3 Tapiawala SN, Tinckam KJ, Cardella CJ. et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol 2010; 21: 153-161 doi:10.1681/asn.2009040412
4 Sawyer RG, Crabtree TD, Gleason TG. et al. Impact of solid organ transplantation and immunosuppression on fever, leukocytosis, and physiologic response during bacterial and fungal infections. Clin Transplant 1999; 13: 260-265
5 Fishman JA. Infection in Organ Transplantation. Am J Transplant 2017; 17: 856-879 doi:10.1111/ajt.14208
6 Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614
7 Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990; 12 (Suppl. 07) S701-S710
8 Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008; 8: 2111-2118
9 Andrassy J, Hoffmann VS, Rentsch M. et al. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis. Transplantation 2012; 94: 1208-1217 doi:10.1097/TP.0b013e3182708e56
10 Allen UD, Preiksaitis JK. AST Infectious Diseases Community of Practice. Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 04) 107-120 doi:10.1111/ajt.12104
11 Pascual J, Royuela A, Fernandez AM. et al. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis 2016; 18: 819-831 doi:10.1111/tid.12601
12 San-Juan R, Comoli P, Caillard S. et al. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Microbiol Infect 2014; 20 (Suppl. 07) 109-118 doi:10.1111/1469-0691.12534
13 Jouve T, Rostaing L, Malvezzi P. Place of mTOR inhibitors in management of BKV infection after kidney transplantation. J Nephropathol 2016; 5: 1-7 doi:10.15171/jnp.2016.01
14 Martin SI, Fishman JA. AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 2013; 13 (Suppl. 04) 272-279 doi:10.1111/ajt.12119
15 Morelon E, Stern M, Kreis H. Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000; 343: 225-226 doi:10.1056/NEJM200007203430317
16 Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant 2012; 2: 74-83 doi:10.5500/wjt.v2.i5.74
17 Wimmer CD, Rentsch M, Crispin A. et al. The janus face of immunosuppression – de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 2007; 71: 1271-1278
18 Webster AC, Wong G, Craig JC. et al. Managing cancer risk and decision making after kidney transplantation. Am J Transplant 2008; 8: 2185-2191 doi:10.1111/j.1600-6143.2008.02385.x
19 Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med 2013; 3: pii:a015677 doi:10.1101/cshperspect.a015677
20 Engels EA, Pfeiffer RM, Fraumeni jr. JF. et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306: 1891-1901 doi:10.1001/jama.2011.1592
21 Ramsay HM, Fryer AA, Hawley CM. et al. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002; 147: 950-956
22 Citores MJ, Lucena JL, de la Fuente S. et al. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019; 11: 50-64 doi:10.4254/wjh.v11.i1.50
23 Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep 2013; 8: 173-183 doi:10.1007/s11899-013-0162-5
24 Stallone G, Schena A, Infante B. et al. Sirolimus for Kaposiʼs sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323
25 OʼDonovan P, Perrett CM, Zhang X. et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-1874 doi:10.1126/science.1114233
26 Rivera A, Maxwell SA. The p 53-induced gene-6 (proline oxidase) mediates apoptosis through a calcineurin-dependent pathway. J Biol Chem 2005; 280: 29346-29354 doi:10.1074/jbc.M504852200
27 Guba M, von Breitenbuch P, Steinbauer M. et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135
28 Kim TJ, Kim N, Kang HJ. et al. FK506 causes cellular and functional defects in human natural killer cells. J Leukoc Biol 2010; 88: 1089-1097 doi:10.1189/jlb.0310148
29 Lee YR, Yang IH, Lee YH. et al. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 2005; 105: 3951-3955 doi:10.1182/blood-2004-10-3927
30 van Kesteren PC, Beems RB, Luijten M. et al. DNA repair-deficient Xpa/p 53 knockout mice are sensitive to the non-genotoxic carcinogen cyclosporine A: escape of initiated cells from immunosurveillance?. Carcinogenesis 2009; 30: 538-543 doi:10.1093/carcin/bgp013
31 Wolf S, Hoffmann VS, Habicht A. et al. Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months. PLoS One 2018; 13: e0194975 doi:10.1371/journal.pone.0194975
32 Acuna SA, Huang JW, Scott AL. et al. Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. Am J Transplant 2017; 17: 103-114 doi:10.1111/ajt.13978
33 Campbell SB, Walker R, Tai SS. et al. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146-1156 doi:10.1111/j.1600-6143.2012.04004.x